Kodiak Sciences rises after eye-disease drugs meet trial goals
BUZZ-Kodiak Sciences rises after eye-disease drugs meet trial goals ** Shares of drug developer Kodiak Sciences KOD.O rise 43.9% to $46.56 premarket
** Co says its experimental drugs Zenkuda and tabirafusp-ted met the main goals of a late-stage trial in patients with wet age-related macular degeneration
** Both drugs achieved vision gains at one year that were not inferior to aflibercept, the comparison treatment
** Wet age-related macular degeneration causes abnormal blood vessels to leak beneath the retina and can lead to loss of central vision
** About 54% of Zenkuda patients reached a six-month dosing interval, potentially reducing the number of eye injections needed
** Both drugs showed safety broadly consistent with aflibercept; Kodiak plans further analyses to identify which patients may benefit most from tabirafusp-ted
** Co plans to seek US approval for Zenkuda in Q4 2026, using results from five successful late-stage studies across three retinal diseases
** KOD up 15.7% YTD, as of last close
(Reporting by Kunal Das in Bengaluru)
Recent news on Regeneron Pharmaceuticals
See all newsEyePoint to halve workforce after experimental drug fails second late-stage trial (updated)
EyePoint to cut workforce by half after experimental drug fails second late-stage trial
Brief: Sanofi, pCPA Sign Letter Of Intent For Dupixent® Across Four Indications In Dermatology, Respiratory Care
Brief: Regeneron Pharmaceuticals Says Pasatru Shows Sustained Efficacy & Consistent Safety Profile From Weeks 56 To 84
Brief: Regeneron Pharmaceuticals - Sanofi Enter Sixth Amendment To License And Collaboration Agreement